BD40 - Chronic Atherosclerotic Obstructive Arterial Disease: Complete ICD-11 Coding Guide
1. Introduction
Chronic atherosclerotic obstructive arterial disease represents one of the most prevalent peripheral vascular conditions in contemporary clinical practice. This pathology is characterized by progressive formation of atheroma plaques on arterial walls, resulting in luminal narrowing and compromise of blood flow to peripheral tissues. The underlying atherosclerotic process involves lipid accumulation, smooth muscle cell proliferation, chronic inflammation, and eventual calcification of affected arteries.
The clinical importance of this condition transcends local symptoms, since patients with peripheral obstructive arterial disease present significantly elevated global cardiovascular risk. The presence of atherosclerosis in peripheral territory frequently indicates systemic disease, with simultaneous involvement of other vascular beds, including coronary and cerebral arteries. This condition affects millions of people globally, with increasing incidence due to population aging and increased prevalence of cardiovascular risk factors such as diabetes, hypertension, smoking, and dyslipidemia.
From an epidemiological perspective, chronic obstructive arterial disease represents an important cause of morbidity, functional disability, and reduced quality of life. In advanced stages, it can result in critical limb ischemia, ischemic ulcers, and even amputations. Precise coding using ICD-11 code BD40 is fundamental for adequate epidemiological surveillance, health resource planning, appropriate allocation of treatments, clinical research, and procedure reimbursement. Correct documentation enables longitudinal patient tracking, outcome analysis, and implementation of evidence-based preventive strategies.
2. Correct ICD-11 Code
Code: BD40
Description: Chronic atherosclerotic arterial obstructive disease
Parent category: Chronic arterial obstructive disease
The code BD40 in the ICD-11 classification specifically designates chronic arterial obstructive disease of atherosclerotic nature with proven or strongly presumed etiology. This code belongs to the chapter on diseases of the circulatory system and is positioned within the broader category of chronic arterial obstructive diseases, reflecting the progressive and persistent nature of this condition.
The specificity of this code resides in the clear identification of the atherosclerotic pathophysiological mechanism as the primary cause of arterial obstruction. This distinction is clinically relevant because it differentiates this condition from other causes of chronic arterial obstruction, such as vasculitis, fibromuscular dysplasia, extrinsic compressions, or traumatic etiologies. Atherosclerosis as the underlying process implies specific therapeutic approaches, including rigorous control of cardiovascular risk factors, antiplatelet therapy, statins in adequate doses, and lifestyle modifications.
The correct utilization of this code allows precise identification of patients who would benefit from vascular rehabilitation programs, screening for atherosclerotic disease in other territories, and cardiovascular risk stratification. Furthermore, it facilitates comparative studies on the effectiveness of different therapeutic interventions and analysis of disease progression patterns in different populations.
3. When to Use This Code
The code BD40 should be applied in specific clinical situations where there is clear evidence of chronic obstructive arterial disease with atherosclerotic etiology. Below, we present detailed practical scenarios:
Scenario 1: Atherosclerotic Intermittent Claudication A 68-year-old patient, smoker for 40 years, with type 2 diabetes, presents with bilateral calf pain when walking distances greater than 200 meters, with relief after a few minutes of rest. Physical examination reveals palpable femoral pulses, but absence of popliteal, posterior tibial, and dorsalis pedis pulses bilaterally. Ankle-brachial index (ABI) of 0.65 bilaterally. Doppler ultrasound demonstrates calcified atherosclerotic plaques in superficial femoral arteries with significant stenoses. This is the classic scenario for coding as BD40.
Scenario 2: Critical Limb Ischemia Patient with a history of progressive claudication for 5 years, now developing rest pain in the right foot, especially at night, requiring the limb to be kept in a dependent position for relief. Presence of ischemic ulcer on the right hallux. Arteriography reveals diffuse atherosclerotic disease with occlusions in multiple infrainguinal arterial segments. In this advanced case of peripheral atherosclerotic disease, BD40 is the appropriate code.
Scenario 3: Aortoiliac Atherosclerotic Disease A 62-year-old male patient with progressive erectile dysfunction, claudication in bilateral buttocks and thighs (Leriche syndrome). Angiotomography demonstrates atherosclerotic occlusion of the aortic bifurcation with extensive involvement of the common iliac arteries. Presence of extensive vascular calcifications. This pattern of proximal atherosclerotic disease justifies BD40 coding.
Scenario 4: Asymptomatic Peripheral Arterial Disease Detected on Screening A diabetic patient undergoing preventive vascular screening, asymptomatic, but with ABI of 0.85 and increased intimal-medial thickness on carotid ultrasound. Doppler of lower limbs reveals atherosclerotic plaques in femoral arteries without hemodynamically significant stenoses. Even in the absence of symptoms, the presence of objectively documented atherosclerotic disease allows the use of BD40.
Scenario 5: Atherosclerosis of Renal Arteries A hypertensive patient with difficult-to-control blood pressure on multiple antihypertensive medications, presenting with progressive renal insufficiency. Angioresonance demonstrates bilateral atherosclerotic stenosis of renal arteries greater than 70%. Presence of concomitant atherosclerotic disease in other territories. Chronic obstructive renal atherosclerosis is appropriately coded as BD40.
Scenario 6: Atherosclerotic Disease of Visceral Arteries Patient with mesenteric angina, presenting with postprandial abdominal pain, weight loss, and fear of eating. Angiographic investigation reveals critical atherosclerotic stenoses in the celiac trunk and superior mesenteric artery. This presentation of chronic mesenteric ischemia due to atherosclerosis justifies BD40.
4. When NOT to Use This Code
Diagnostic accuracy requires clear knowledge of situations where BD40 should not be applied, directing toward more specific or appropriate codes:
Exclusion for Chronic Intestinal Vascular Disorders: When the clinical presentation primarily involves chronic intestinal manifestations with secondary or functional vascular alterations, the specific code for chronic vascular disorders of the intestine should be used. The distinction lies in the predominantly gastroenterological versus vascular presentation.
Exclusion for Atherosclerotic Cerebrovascular Accidents: Even though atherosclerosis is the underlying mechanism, acute cerebrovascular events caused by atherosclerosis of large intracranial or extracranial arteries have specific codes. BD40 should not be used for acute stroke, but only for chronic peripheral vascular disease.
Exclusion for Coronary Atherosclerosis: Atherosclerotic disease of the coronary arteries has its own specific coding. Even if the patient presents simultaneously with coronary and peripheral disease, each territory should be coded separately with its appropriate codes.
Exclusion for Cold-Related Conditions: Chilblains and frostbite represent injuries from cold exposure, not chronic atherosclerotic processes. Although they may cause peripheral vascular symptoms, the pathophysiology is completely distinct.
Exclusion for Specific Asymptomatic Stenoses: When there is asymptomatic intracranial or extracranial arterial stenosis detected on imaging studies, there is a specific code that differentiates this situation from symptomatic disease or peripheral location disease.
Differentiation of Non-Atherosclerotic Causes: It is essential to distinguish arterial obstructions from other etiologies such as Takayasu arteritis, thromboangiitis obliterans (Buerger disease), fibromuscular dysplasia, or extrinsic compressions. These conditions have pathophysiology, treatment, and prognosis distinct from atherosclerosis.
5. Step-by-Step Coding Process
Step 1: Assess Diagnostic Criteria
Diagnostic confirmation of chronic atherosclerotic obstructive arterial disease requires a systematic approach combining clinical history, physical examination, and complementary methods. Initially, the presence of characteristic symptoms is investigated, such as intermittent claudication, rest pain, cutaneous trophic changes, or ischemic ulcers. Physical examination should include careful palpation of peripheral pulses, auscultation for arterial bruits, assessment of skin temperature and coloration, and inspection of trophic lesions.
The ankle-brachial index (ABI) constitutes a fundamental diagnostic tool, non-invasive and of high sensitivity. Values below 0.90 suggest obstructive arterial disease, while values below 0.40 indicate critical ischemia. Ultrasound with color Doppler allows direct visualization of atherosclerotic plaques, quantification of stenoses, and assessment of flow patterns. Angiographic methods, whether by computed tomography, magnetic resonance, or catheterization, provide detailed anatomical mapping of disease extent and severity.
Step 2: Verify Specifiers
Adequate documentation should include severity specification according to Fontaine or Rutherford classification. Stage I (asymptomatic), stage II (claudication), stage III (rest pain), and stage IV (trophic lesions or gangrene) represent a progressive spectrum of severity. Precise anatomical location must be documented: aortoiliac, femoropopliteal, infrapopliteal, or combinations.
Additional characteristics include pattern of involvement (focal versus diffuse), presence of vascular calcification, collateral circulation status, and response to previous treatments. Duration of symptoms and rate of progression are also relevant for characterization as chronic disease.
Step 3: Differentiate from Other Codes
BD41 - Chronic non-atherosclerotic obstructive arterial disease: The fundamental difference lies in etiology. BD41 applies to obstructions from vasculitis, dysplasias, compressions, or traumatic causes. Patient age, pattern of lesion distribution, presence of systemic manifestations, and angiographic characteristics aid in differentiation. Atherosclerosis typically affects older patients with cardiovascular risk factors, while non-atherosclerotic causes frequently affect younger individuals with atypical patterns.
BD42 - Raynaud phenomenon: This condition is characterized by episodic vasospasm triggered by cold or emotional stress, manifesting with triphasic color changes (pallor, cyanosis, rubor). There is no fixed anatomical obstruction from atherosclerosis, but rather reversible vasomotor dysfunction. The absence of permanent trophic lesions and normal pulses between episodes distinguish Raynaud from BD40.
Step 4: Required Documentation
Checklist of mandatory information for adequate coding:
- Detailed description of symptoms with severity classification
- Results of complete vascular physical examination with pulse status
- Bilateral ankle-brachial index value
- Results of vascular imaging studies with description of atherosclerotic lesions
- Precise anatomical location of obstructions
- Presence and status of cardiovascular risk factors
- Previous treatments performed and responses obtained
- Assessment of vascular involvement in other territories
- Functional classification and impact on quality of life
6. Complete Practical Example
Clinical Case:
A 71-year-old male patient presents to vascular consultation reporting progressive difficulty walking for approximately 18 months. He reports that initially he could walk long distances without discomfort, but in recent months has developed burning pain in the calves, mainly on the right, which occurs after walking about 150 meters on flat ground. The pain forces him to stop, improving completely after 3-5 minutes of rest while standing. He denies pain at rest or skin changes in the feet.
Past medical history reveals type 2 diabetes mellitus diagnosed 15 years ago, on irregular use of metformin, with recent glycated hemoglobin of 8.2%. Arterial hypertension for 20 years, controlled with enalapril and hydrochlorothiazide. Known dyslipidemia, without regular statin use. 50 pack-year smoking history, having quit 2 years ago. Denies history of prior coronary or cerebrovascular disease.
Physical examination reveals patient in good general condition, blood pressure 142/88 mmHg, heart rate 76 bpm regular. Cardiovascular examination without cardiac murmurs. Vascular examination: symmetric carotid pulses without murmurs; bilateral normal brachial pulses; right femoral pulse with audible systolic murmur, diminished amplitude; left femoral pulse palpable, normal amplitude; absence of popliteal, posterior tibial, and dorsalis pedis pulses on the right; left popliteal pulse palpable, diminished tibials. Absence of trophic lesions or ulcers. Preserved skin temperature. Capillary refill time of 4 seconds in the right foot.
Complementary Investigation:
Ankle-brachial index: right lower limb 0.58; left lower limb 0.82. Color Doppler ultrasound of lower limbs demonstrates: right common femoral artery with calcified atherosclerotic plaque causing approximately 50% stenosis; right superficial femoral artery with multiple atherosclerotic plaques, one in the middle portion causing 80-90% stenosis; right popliteal artery with monophasic flow; left superficial femoral artery with non-obstructive plaques. Complete blood count, renal function, and lipid profile requested reveal normal creatinine, LDL-cholesterol 165 mg/dL, HDL 38 mg/dL, triglycerides 210 mg/dL.
Coding Step by Step:
Criteria Analysis: The patient presents with classic intermittent claudication (Fontaine IIa/IIb), with defined claudication distance, relief with rest, and absence of symptoms at rest. Physical examination confirms reduction of peripheral pulses on the right. The ABI of 0.58 on the right objectively confirms significant obstructive arterial disease. Ultrasound documents the presence of calcified atherosclerotic plaques with hemodynamically significant stenoses.
Code Selected: BD40 - Chronic atherosclerotic obstructive arterial disease
Complete Justification: The diagnosis of chronic obstructive arterial disease is established by the presence of characteristic symptoms for 18 months (chronicity), objective confirmation by pathological ABI, and angiographic documentation of obstructions. The atherosclerotic etiology is evident by the presence of multiple risk factors (diabetes, hypertension, dyslipidemia, prior smoking), advanced age, presence of calcified plaques on ultrasound, and typical distribution pattern (superficial femoral). There is no evidence of other etiologies such as vasculitis, trauma, or extrinsic compressions.
Complementary Codes: Codes should be added for type 2 diabetes mellitus, arterial hypertension, and dyslipidemia, in addition to a Z code for smoking history. Documentation of severity (Fontaine IIb) and location (right femoropopliteal) should be included in the medical record.
7. Related Codes and Differentiation
Within the Same Category:
BD41: Chronic non-atherosclerotic obstructive arterial disease
The fundamental differentiation between BD40 and BD41 is based exclusively on the etiology of arterial obstruction. BD41 is used when the cause of obstruction is not atherosclerosis, including conditions such as Takayasu arteritis (large vessel vasculitis), thromboangiitis obliterans or Buerger disease (small and medium vessel vasculitis associated with smoking), fibromuscular dysplasia (non-atherosclerotic proliferation of the arterial wall), extrinsic compressions by tumors or fibrous bands, and sequelae of vascular trauma.
Clinically, BD41 frequently affects younger patients, presents atypical anatomical distribution (such as involvement of distal arteries in young patients without risk factors), may be associated with systemic manifestations (fever, weight loss, joint symptoms in vasculitis), and imaging studies reveal distinct characteristics such as long smooth narrowings in fibromuscular dysplasia or "beads on a string" appearance. The absence of traditional cardiovascular risk factors in a young patient with obstructive arterial disease suggests non-atherosclerotic etiology.
BD42: Raynaud phenomenon
Raynaud phenomenon represents a functional vasomotor disorder characterized by episodes of reversible arterial vasospasm, typically triggered by exposure to cold or emotional stress. It manifests classically by triphasic color changes in the fingers: initial pallor (ischemic phase due to vasoconstriction), followed by cyanosis (deoxygenation) and finally rubor (reactive hyperemia).
The distinction from BD40 is clear: Raynaud does not involve fixed anatomical obstruction by atherosclerosis, but rather transient vasomotor dysfunction. Symptoms are episodic and completely reversible, there is no progression to critical ischemia or permanent trophic lesions (except in severe cases associated with connective tissue diseases), and arterial pulses are normal between episodes. Vascular studies do not demonstrate obstructive atherosclerotic lesions. Raynaud may be primary (idiopathic) or secondary to connective tissue diseases such as systemic sclerosis.
Differential Diagnoses:
Diabetic peripheral neuropathy may mimic claudication symptoms, but typically causes symptoms at rest, paresthesias, nocturnal burning and does not improve with stopping during walking. Lumbar canal stenosis causes neurogenic pseudoclaudication, improving with spinal flexion and worsening with extension, in contrast to vascular claudication. Chronic venous insufficiency causes discomfort in the lower limbs, but typically worsens at the end of the day, improves with elevation and is associated with edema and venous skin changes.
8. Differences with ICD-10
In the ICD-10 classification, chronic atherosclerotic obstructive arterial disease was coded primarily as I70.2 (atherosclerosis of arteries of the extremities), with subdivisions based on location and presence of complications such as gangrene (I70.24) or ulcer (I70.25). Other peripheral atherosclerotic locations used codes such as I70.1 (renal atherosclerosis) or I70.8 (atherosclerosis of other arteries).
The transition to ICD-11 with code BD40 represents a significant conceptual change. The new classification emphasizes the obstructive and chronic nature of the disease, grouping different peripheral vascular territories under a unified code when the etiology is atherosclerotic. This approach better reflects the current understanding of atherosclerosis as a systemic disease, facilitating identification of patients with elevated cardiovascular risk regardless of the specific territory affected.
Practically, ICD-11 simplifies coding by reducing excessive anatomical subdivisions, allowing for more consistent documentation. The specification of location, severity, and complications is now done through standardized extensions and qualifiers, rather than completely distinct codes. This change facilitates epidemiological analyses, comparative studies, and longitudinal patient tracking. Healthcare professionals should familiarize themselves with the new structure to ensure accurate coding and continuity in clinical documentation during the transition between classification systems.
9. Frequently Asked Questions
How is chronic atherosclerotic obstructive arterial disease diagnosed?
The diagnosis combines clinical evaluation and complementary methods. Clinically, the history of intermittent claudication (muscle pain during exercise that relieves with rest), pain at rest, cutaneous alterations, or ulcers is investigated. The vascular physical examination includes pulse palpation, auscultation of arterial bruits, and inspection of lesions. The ankle-brachial index (ABI), a simple and non-invasive measurement, is fundamental: values below 0.90 confirm arterial disease. Doppler ultrasound visualizes atherosclerotic plaques and quantifies stenoses. Complex cases may require angiography computed tomography, magnetic resonance angiography, or conventional arteriography for detailed therapeutic planning.
Is treatment available in public health systems?
Yes, treatment for chronic atherosclerotic obstructive arterial disease is generally available in public health systems, although accessibility may vary according to local resources. Initial conservative treatment includes modification of risk factors, supervised exercise, antiplatelet medications, and statins, generally accessible. Revascularization procedures such as angioplasty with stent or bypass surgery are also offered in specialized centers, prioritized according to severity. Patients with critical ischemia or incapacitating claudication have priority for interventions. Supervised vascular rehabilitation programs are progressively being implemented in various health systems.
How long does treatment last?
Chronic atherosclerotic obstructive arterial disease requires continuous and lifelong treatment, as it represents a manifestation of systemic atherosclerotic process. Control of risk factors (diabetes, hypertension, dyslipidemia) is permanent. Antiplatelet medications and statins are maintained indefinitely to prevent cardiovascular events. Supervised exercise programs for claudication typically last 3-6 months with sustained benefits if regular physical activity is maintained. After revascularization procedures, periodic vascular follow-up is necessary to monitor patency and detect disease progression in other segments.
Can this code be used in medical certificates?
Yes, the code BD40 can and should be used in official medical documentation, including certificates when appropriate. In certificates to justify work leave, ICD-11 coding provides diagnostic specificity while maintaining adequate confidentiality. The severity of the disease determines the need and duration of leave: mild claudication may not require leave, while critical ischemia, revascularization procedures, or postoperative complications justify prolonged absences. Documentation should be complemented with a functional description of the impact on the patient's specific work activities.
Can asymptomatic patients receive this code?
Yes, chronic atherosclerotic obstructive arterial disease can be diagnosed even in asymptomatic patients when detected on screening or investigation of other conditions. Approximately one-third of patients with abnormal ABI are asymptomatic. Early detection is valuable as it identifies individuals with elevated cardiovascular risk who benefit from intensification of risk factor control. Even when asymptomatic, these patients require antiplatelet therapy, statins, and lifestyle modifications. The code BD40 is appropriate when there is objective documentation of obstructive atherosclerosis, regardless of symptoms.
What is the difference between peripheral arterial disease and chronic atherosclerotic obstructive arterial disease?
Peripheral arterial disease is a broader term that encompasses all conditions affecting arteries outside the heart and brain, including atherosclerotic and non-atherosclerotic causes, acute and chronic. Chronic atherosclerotic obstructive arterial disease (BD40) is a specific subgroup characterized by progressive obstruction of atherosclerotic etiology with chronic evolution. Diagnostic specificity is important to guide appropriate treatment and prognosis. While peripheral arterial disease may include aneurysms, vasculitis, or acute emboli, BD40 refers specifically to chronic atherosclerotic obstructions.
Can obstructive arterial disease regress with treatment?
Complete regression of established atherosclerotic plaques is uncommon, but stabilization and even partial reduction are possible with aggressive treatment. Studies demonstrate that rigorous control of risk factors, especially with high-potency statins, can stabilize plaques, reduce inflammation, and improve endothelial function. Clinically, patients frequently experience significant symptomatic improvement through development of collateral circulation stimulated by supervised exercise, even without anatomic regression of obstructions. The primary goal of treatment is to prevent progression, reduce cardiovascular events, and improve quality of life, rather than completely reverse atherosclerotic lesions.
Which medical specialties treat this condition?
Chronic atherosclerotic obstructive arterial disease is typically managed by vascular surgeons and angiologists, specialists in peripheral vascular diseases. Cardiologists frequently participate in care due to the elevated cardiovascular risk of these patients. Endocrinologists are essential for diabetic patients. Interventional radiologists perform endovascular procedures. Optimal management is multidisciplinary, including physical therapists for vascular rehabilitation, nurses specialized in wound care for ischemic ulcers, and mental health professionals when indicated. Coordination between specialties optimizes outcomes and addresses the complexity of this systemic condition.
Conclusion
Precise coding of chronic atherosclerotic obstructive arterial disease using BD40 in ICD-11 is fundamental for adequate clinical documentation, epidemiological surveillance, and appropriate health resource management. Understanding the diagnostic criteria, application situations, specific exclusions, and differentiation of similar conditions ensures correct use of this code. The systematic approach presented in this guide facilitates the transition from ICD-10 to ICD-11, promoting consistency in global clinical practice and contributing to continuous improvement in care for patients with this prevalent and clinically significant cardiovascular condition.
External References
This article was developed based on reliable scientific sources:
- 🌍 WHO ICD-11 - Chronic atherosclerotic obstructive arterial disease
- 🔬 PubMed Research on Chronic atherosclerotic obstructive arterial disease
- 🌍 WHO Health Topics
- 📊 Clinical Evidence: Chronic atherosclerotic obstructive arterial disease
- 📋 Ministry of Health - Brazil
- 📊 Cochrane Systematic Reviews
References verified on 2026-02-03